Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 2, 2008, Pages 181-186

  Huisman, Cynthia ^a   Meijer, Ellen ^a   Petersen, Eefke J ^a   Lokhorst, Henk M ^a   Verdonck, Leo F ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Acute myelogenous leukemia; Reduced intensity conditioning; Stem cell transplantation

Indexed keywords

CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; IDARUBICIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THYMOCYTE ANTIBODY; VALACICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA MATCHING; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW ENERGY RADIATION; MALE; MYELODYSPLASTIC SYNDROME; REDUCED INTENSITY CONDITIONING; SIBLING; SURVIVAL RATE; THERAPY EFFECT; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; VIRUS REACTIVATION; VOLUNTEER; WHOLE BODY RADIATION;

ADULT; AGE FACTORS; AGED; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; OPPORTUNISTIC INFECTIONS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 38349186890     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.09.017     Document Type: Article

References (27)

1. Mayer R.J., Davis R.B., Schiffer C.A., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331 (1994) 896-903
2. Martino R., Caballero M.D., Simon J.A., et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 100 (2002) 2243-2245
3. Kolb H.J., Schmid C., Barrett A.J., and Schendel D.J. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103 (2004) 767-776
4. Baron F., and Storb R. Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. Curr Opin Hematol 14 (2007) 145-151
5. Blaise D., Vey N., Faucher C., and Mohty M. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 92 (2007) 533-541
6. Lazarus H.M., and Rowe J.M. Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct. Leukemia 20 (2006) 1673-1682
7. Niederwieser D., Lange T., Cross M., Basara N., and Al Ali H. Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML. Best Pract Res Clin Haematol 19 (2006) 825-838
8. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 19 (2005) 2304-2312
9. de Lima M., Anagnostopoulos A., Munsell M., et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104 (2004) 865-872
10. Scott B.L., Sandmaier B.M., Storer B., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20 (2006) 128-135
11. Shimoni A., Hardan I., Shem-Tov N., et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 20 (2006) 322-328
12. Mohty M., de Lavallade H., Ladaique P., et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 19 (2005) 916-920
13. Estey E., de Lima M., Tibes R., et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 109 (2007) 1395-1400
14. Finke J., and Nagler A. Viewpoint: what is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning-is there still an upper age limit? A focus on myeloid neoplasia. Leukemia 21 (2007) 1357-1362
15. Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 23 (2005) 1993-2003
16. Storb R., Yu C., Barnett T., et al. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 94 (1999) 1131-1136
17. Thomas E.D., Storb R., Clift R.A., et al. Bone-marrow transplantation (second of two parts). N Engl J Med 292 (1975) 895-902
18. Huisman C., de Weger R.A., de Vries L., Tilanus M.G., and Verdonck L.F. Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transplant 39 (2007) 285-291
19. Cornelissen J.J., van Putten W.L., Verdonck L.F., et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood 109 (2007) 3658-3666
20. Alyea E.P., Kim H.T., Ho V., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105 (2005) 1810-1814
21. Hegenbart U., Niederwieser D., Sandmaier B.M., et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 24 (2006) 444-453
22. Sayer H.G., Kroger M., Beyer J., et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 31 (2003) 1089-1095
23. Hallemeier C., Girgis M., Blum W., et al. Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants. Biol Blood Marrow Transplant 10 (2004) 310-319
24. Tauro S., Craddock C., Peggs K., et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 23 (2005) 9387-9393
25. Wong R., Giralt S.A., Martin T., et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 102 (2003) 3052-3059
26. Meijer E., Cornelissen J.J., Lowenberg B., and Verdonck L.F. Antithymocyteglobulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T-cell-depleted grafts from matched unrelated donors: a dose-finding study. Exp Hematol 31 (2003) 1026-1030
27. Ho A.Y., Pagliuca A., Kenyon M., et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 104 (2004) 1616-1623